In today’s blog we’ll shine a light on a March 24, 2016 report, The Lancet: Public health and international drug policy (2016), from The Lancet and the Johns Hopkins Bloomberg School of Public Health.
With implications for the medical marijuana community as well as supporters of the legalization of marijuana and beyond, the report highlights the directive given to experts in drug policy and public health to review the global evidence of current drug policies on health impacts. It also implores the United Nations to rethink its drug policy and adopt a number of major changes, including an end to cannabis prohibition:
The world has also taken sharp notice of the cannabis-legalisation experiences of the US states of Washington, Colorado, Oregon, Alaska, and the District of Columbia in a country where opposition to drug legalisation has been deep, and of the nationwide cannabis-legalisation experiment in Uruguay. The ﬁscal imperative of reducing incarceration and the fear of adulterants in cannabis obtained illegally have been part of the debates about the US policy changes.
Although changes in the legal status of cannabis do not signal changes in prohibition-oriented policies with respect to other drugs in the USA, concrete experiences with large-scale regulated cannabis markets provide an opportunity for rigourous assessments that will inform larger drug-policy debates.
Find the full report below.